MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2026.117039

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2026

Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.

Valent Jason, Zonder Jeffrey, Swenson E Scott, Catini Julia, Manwani Richa, Ahuja Bhavna, Khan Zilehuma, Liedtke Michaela

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Light chain (AL) amyloidosis is a rare, potentially fatal plasma cell dyscrasia (PCD). Misfolded immunoglobulin light chains aggregate into amyloid fibrils, which deposit in organs. Current therapies suppress light chain overproduction but do not directly remove existing amyloid deposits. Anselamimab (CAEL-101) is an investigational monoclonal antibody designed to remove light chain amyloid fibrils. We evaluated its safety and tolerability combined with standard of care (SoC) anti-PCD therapy in participants with AL amyloidosis.

METHODS

Adults with AL amyloidosis (European modification of Mayo 2004 stages I-IIIa) and measurable hematologic disease entered NCT04304144, a phase 2, multicentre, open-label, sequential-cohort, dose-selection study. Participants received 4 weekly anselamimab infusions (part A 500-1000 mg/m2; part B 1000 mg/m2) concurrent with SoC. Anselamimab was subsequently administered every 2 weeks until Week 50 and then optionally every 4 weeks until study end. Primary outcome was safety through 140 days post-treatment.

RESULTS

Of 25 participants, 13 received anselamimab + CyBorD (cyclophosphamide, bortezomib, dexamethasone; Part A) and 12 received anselamimab + CyBorD + daratumumab (Part B). All participants experienced at least 1 treatment-emergent adverse event (TEAE), most mild-to-moderate. Sixteen participants (64.0%) experienced serious TEAEs. Four participants (16.0%) discontinued study drug because of TEAEs, and 3 participants (12.0%) experienced fatal TEAEs. All serious and fatal TEAEs were adjudicated as study-drug-unrelated. No dose-limiting toxicities occurred. Best cardiac responses occurred at Week 50 (47.4% of evaluable participants) and best renal responses at Weeks 62 and 98 (85.7% of evaluable participants).

CONCLUSIONS

Anselamimab was well tolerated. Most common TEAEs were consistent with AL amyloidosis or anti-PCD therapy.

Для цитирования: Valent Jason, Zonder Jeffrey, Swenson E Scott, Catini Julia, Manwani Richa, Ahuja Bhavna, Khan Zilehuma, Liedtke Michaela. Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.. European journal of cancer (Oxford, England : 1990). 2026. DOI: 10.1016/j.ejca.2026.117039.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.